Financial Management Professionals’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.82K Hold
1,410
– – ﹤0.01% 653
2026
Q2
$5.18K Hold
1,410
– – ﹤0.01% 682
2026
Q1
$4.33K Hold
1,410
– – ﹤0.01% 639
2025
Q4
$5.77K Hold
1,410
– – ﹤0.01% 604
2025
Q3
$6.88K Hold
1,410
– – ﹤0.01% 566
2025
Q2
$7.14K Buy
+1,410
New +$6.93K ﹤0.01% 590
2025
Q1
– Sell
-840
Closed -$5.68K – 1038
2024
Q4
$5.68K Hold
840
– – ﹤0.01% 596
2024
Q3
$6K Hold
840
– – ﹤0.01% 618
2024
Q2
$6K Hold
840
– – ﹤0.01% 575
2024
Q1
$8K Buy
+840
New +$9.35K ﹤0.01% 582

Other funds holding RXRX

Financial Management Professionals's RXRX Position: Q3 2026 in Review

Financial Management Professionals held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 1,410 shares worth $5.82K. The position accounts for ﹤0.01% of the portfolio, ranked #653.

Financial Management Professionals first reported a position in RXRX in Q1 2024 and has held it in 10 quarters since. The position peaked at $8K in Q1 2024. 353 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Financial Management Professionals held 1,410 shares of Recursion Pharmaceuticals worth $5.82K as of Q3 2026.
  • Financial Management Professionals left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Financial Management Professionals's portfolio in Q3 2026, its #653 holding.
  • Financial Management Professionals first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Financial Management Professionals's Recursion Pharmaceuticals position peaked at $8K in Q1 2024.
  • 353 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Financial Management Professionals's 13F filing for Q3 2026, filed 23 Oct 2026.